23andMe Holding Co.

NasdaqCM:ME 주식 보고서

시가총액: US$148.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

23andMe Holding 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Anne Wojcicki

최고 경영자

US$7.4m

총 보상

CEO 급여 비율0.9%
CEO 임기18.7yrs
CEO 소유권19.7%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간데이터 없음

최근 관리 업데이트

Recent updates

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

Jul 13
We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

Jun 15
23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Sep 27

23andMe: Treacherous Path To Profitability

Aug 26

23andMe drops 8% as CFO resigns

Aug 19

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Aug 11
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Q1 2023 Earnings Preview

Aug 07

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive

Jun 15

23andMe: A Genetics Innovator Positioned For Growth

Feb 19

Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

Feb 18
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Nov 21

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Oct 03

Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

Sep 17
Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

23andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding

Jul 19

CEO 보상 분석

Anne Wojcicki 의 보수는 23andMe Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$631m

Mar 31 2024US$7mUS$65k

-US$667m

Dec 31 2023n/an/a

-US$522m

Sep 30 2023n/an/a

-US$336m

Jun 30 2023n/an/a

-US$327m

Mar 31 2023US$63kUS$63k

-US$312m

Dec 31 2022n/an/a

-US$317m

Sep 30 2022n/an/a

-US$315m

Jun 30 2022n/an/a

-US$265m

Mar 31 2022US$33mUS$59k

-US$217m

Dec 31 2021n/an/a

-US$215m

Sep 30 2021n/an/a

-US$170m

Jun 30 2021n/an/a

-US$190m

Mar 31 2021US$20mUS$55k

-US$184m

Mar 31 2020US$51kUS$51k

-US$251m

보상 대 시장: Anne 의 총 보상 ($USD 7.36M )은 US 시장( $USD 1.52M ).

보상과 수익: 회사가 수익성이 없는 동안 Anne 의 보상이 증가했습니다.

CEO

Anne Wojcicki

18.7yrs

테뉴어

US$7,363,723

보상

Ms. Anne Wojcicki is the Co-Founder, CEO & Chair of 23andMe Inc. Ms. Anne had been a Director of Ajax I since October 30, 2020. Ms. Wojcicki serves as a General Partner of Covalence Life Sciences Partners....

리더십 팀

이름위치테뉴어보상소유권
Anne Wojcicki
Co-Founder18.7yrsUS$7.36m19.71%
$ 29.3m
Joseph Selsavage
Chief Financial & Accounting Officer2yrsUS$2.13m0.085%
$ 126.6k
Eli Fry
Vice President of Operationsless than a year데이터 없음데이터 없음
Guy Chayoun
VP, Interim General Counsel & Corporate Secretaryless than a year데이터 없음데이터 없음
Katie Watson
Vice President of Communicationsno data데이터 없음데이터 없음
Jonathan Ward
Chief Marketing Officer2.7yrs데이터 없음데이터 없음
Reza Afkhami
Chief Corporate Development Officer1.3yrs데이터 없음데이터 없음
Savita Pillai
Vice President of People2.1yrs데이터 없음데이터 없음
Jennifer Low
Head of Therapeutics Development6.7yrs데이터 없음데이터 없음
Kent Hillyer
Vice President of Consumer Operationsno data데이터 없음데이터 없음
Daniel Chu
Chief Product Officer2yrs데이터 없음데이터 없음
Tracy Keim
Chief Brand Officer1.2yrs데이터 없음데이터 없음

2.0yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 관리: ME 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.